DOPAMINE SULFATE IN VENTRICULAR CEREBROSPINAL-FLUID AND MOTOR FUNCTION IN PARKINSONS-DISEASE

被引:20
作者
CEDARBAUM, JM
OLANOW, CW
机构
[1] CORNELL UNIV,SCH MED,BURKE REHABILITAT CTR,DEPT NEUROL & NEUROSCI,WHITE PLAINS,NY 10605
[2] REGENERON PHARMACEUT INC,TARRYTOWN,NY
[3] UNIV S FLORIDA,DEPT NEUROL,TAMPA,FL 33620
关键词
D O I
10.1212/WNL.41.10.1567
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We measured sequential plasma and CSF levodopa and CSF dopamine sulfate levels following a single dose of levodopa/carbidopa in two patients with advanced Parkinson's disease (PD). We obtained CSF from an Ommaya reservoir implanted in the lateral ventricle several months earlier at the time of transplantation of adrenal medulla to caudate nucleus and could detect dopamine only in its sulfconjugated form. Peak CSF levodopa and dopamine sulfate levels occurred 1 to 1.5 hours after peak plasma concentration of levodopa. The time course of clinical improvement and worsening correlated precisely with the appearance and disappearance of both levodopa and dopamine sulfate in the CSF. The precise correlation between CSF dopamine sulfate and levodopa indicates that in patients with advanced PD the brain retains some capacity to convert levodopa to dopamine. The transient nature of the correlation between motor fluctuations, CSF levodopa, and CSF dopamine sulfate is consistent with suggestions that in patients with advanced PD there is a diminished capacity to store dopamine synthesized from exogenous levodopa. Dopamine sulfate appears to be a useful index of the availability of dopamine in the parkinsonian brain.
引用
收藏
页码:1567 / 1570
页数:4
相关论文
共 19 条
  • [1] CAHILL DW, 1990, PROG BRAIN RES, V42, P637
  • [2] SIMULTANEOUS DETERMINATION OF LEVODOPA, ITS METABOLITES AND CARBIDOPA IN CLINICAL-SAMPLES
    CEDARBAUM, JM
    WILLIAMSON, R
    KUTT, H
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 415 (02): : 393 - 399
  • [3] MULTICENTER STUDY OF AUTOLOGOUS ADRENAL-MEDULLARY TRANSPLANTATION TO THE CORPUS STRIATUM IN PATIENTS WITH ADVANCED PARKINSONS-DISEASE
    GOETZ, CG
    OLANOW, CW
    KOLLER, WC
    PENN, RD
    CAHILL, D
    MORANTZ, R
    STEBBINS, G
    TANNER, CM
    KLAWANS, HL
    SHANNON, KM
    COMELLA, CL
    WITT, T
    COX, C
    WAXMAN, M
    GAUGER, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (06) : 337 - 341
  • [4] BDNF IS A NEUROTROPHIC FACTOR FOR DOPAMINERGIC-NEURONS OF THE SUBSTANTIA-NIGRA
    HYMAN, C
    HOFER, M
    BARDE, YA
    JUHASZ, M
    YANCOPOULOS, GD
    SQUINTO, SP
    LINDSAY, RM
    [J]. NATURE, 1991, 350 (6315) : 230 - 232
  • [5] CLINICAL, BIOCHEMICAL, AND NEUROPATHOLOGIC FINDINGS FOLLOWING TRANSPLANTATION OF ADRENAL-MEDULLA TO THE CAUDATE-NUCLEUS FOR TREATMENT OF PARKINSONS-DISEASE
    JANKOVIC, J
    GROSSMAN, R
    GOODMAN, C
    PIROZZOLO, F
    SCHNEIDER, L
    ZHU, Z
    SCARDINO, P
    GARBER, AJ
    JHINGRAN, SG
    MARTIN, S
    [J]. NEUROLOGY, 1989, 39 (09) : 1227 - 1234
  • [6] CSF SULFOCONJUGATED CATECHOLAMINES IN MAN - THEIR RELATIONSHIP WITH PLASMA-CATECHOLAMINES
    KUCHEL, O
    HAUSSER, C
    BUU, NT
    TENNESON, S
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1985, 62 (1-2) : 91 - 97
  • [7] PARKINSONS DISEASE - ACTIVITY OF L-DOPA DECARBOXYLASE IN DISCRETE BRAIN REGIONS
    LLOYD, K
    HORNYKIEWICZ, O
    [J]. SCIENCE, 1970, 170 (3963) : 1212 - +
  • [8] LLOYD KG, 1975, J PHARMACOL EXP THER, V195, P453
  • [9] SUPPRESSION OF L-DOPA-INDUCED CIRCLING IN RATS WITH NIGRAL LESIONS BY BLOCKADE OF CENTRAL DOPA-DECARBOXYLASE - IMPLICATIONS FOR MECHANISM OF ACTION OF L-DOPA IN PARKINSONISM
    MELAMED, E
    HEFTI, F
    BITTON, V
    GLOBUS, M
    [J]. NEUROLOGY, 1984, 34 (12) : 1566 - 1570
  • [10] MELAMED E, 1988, PARKINSONS DISEASE M, P87